184 related articles for article (PubMed ID: 33159515)
1. Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein Y; Aloni-Grinstein R; Rotter V
Carcinogenesis; 2020 Dec; 41(12):1635-1647. PubMed ID: 33159515
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
3. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53-a potential player in shaping the tumor-stroma crosstalk.
Stein Y; Aloni-Grinstein R; Rotter V
J Mol Cell Biol; 2019 Jul; 11(7):600-604. PubMed ID: 31318969
[TBL] [Abstract][Full Text] [Related]
5. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
6. The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3.
Vaughan CA; Singh S; Subler MA; Windle JJ; Inoue K; Fry EA; Pillappa R; Grossman SR; Windle B; Andrew Yeudall W; Deb SP; Deb S
Nat Commun; 2021 Jan; 12(1):704. PubMed ID: 33514736
[TBL] [Abstract][Full Text] [Related]
7. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
10. Control of Nucleotide Metabolism Enables Mutant p53's Oncogenic Gain-of-Function Activity.
Schmidt V; Nagar R; Martinez LA
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29257071
[TBL] [Abstract][Full Text] [Related]
11. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
14. Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development.
Aubrey BJ; Janic A; Chen Y; Chang C; Lieschke EC; Diepstraten ST; Kueh AJ; Bernardini JP; Dewson G; O'Reilly LA; Whitehead L; Voss AK; Smyth GK; Strasser A; Kelly GL
Genes Dev; 2018 Nov; 32(21-22):1420-1429. PubMed ID: 30366906
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 partners in crime.
Kim MP; Lozano G
Cell Death Differ; 2018 Jan; 25(1):161-168. PubMed ID: 29099488
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
Yue X; Zhang C; Zhao Y; Liu J; Lin AW; Tan VM; Drake JM; Liu L; Boateng MN; Li J; Feng Z; Hu W
Genes Dev; 2017 Aug; 31(16):1641-1654. PubMed ID: 28947497
[TBL] [Abstract][Full Text] [Related]
17. A dominant-negative effect drives selection of
Boettcher S; Miller PG; Sharma R; McConkey M; Leventhal M; Krivtsov AV; Giacomelli AO; Wong W; Kim J; Chao S; Kurppa KJ; Yang X; Milenkowic K; Piccioni F; Root DE; Rücker FG; Flamand Y; Neuberg D; Lindsley RC; Jänne PA; Hahn WC; Jacks T; Döhner H; Armstrong SA; Ebert BL
Science; 2019 Aug; 365(6453):599-604. PubMed ID: 31395785
[No Abstract] [Full Text] [Related]
18. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
19. From mutational inactivation to aberrant gain-of-function: Unraveling the structural basis of mutant p53 oncogenic transition.
Olotu FA; Soliman MES
J Cell Biochem; 2018 Mar; 119(3):2646-2652. PubMed ID: 29058783
[TBL] [Abstract][Full Text] [Related]
20. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic.
Kadosh E; Snir-Alkalay I; Venkatachalam A; May S; Lasry A; Elyada E; Zinger A; Shaham M; Vaalani G; Mernberger M; Stiewe T; Pikarsky E; Oren M; Ben-Neriah Y
Nature; 2020 Oct; 586(7827):133-138. PubMed ID: 32728212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
